Attention-Deficit/Hyperactivity Disorder Animal Model Presents Retinal Alterations and Methylphenidate Has a Differential Effect in ADHD versus Control Conditions.

attention-deficit/hyperactivity disorder methylphenidate neuroinflammation retina visual function

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
15 Apr 2023
Historique:
received: 01 03 2023
revised: 07 04 2023
accepted: 11 04 2023
medline: 28 4 2023
pubmed: 28 4 2023
entrez: 28 4 2023
Statut: epublish

Résumé

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most prevalent neurodevelopmental disorders. Interestingly, children with ADHD seem to experience more ophthalmologic abnormalities, and the impact of methylphenidate (MPH) use on retinal physiology remains unclear. Thus, we aimed to unravel the retina's structural, functional, and cellular alterations and the impact of MPH in ADHD versus the control conditions. For that, spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY) were used as animal models of ADHD and the controls, respectively. Animals were divided into four experimental groups as follows: WKY vehicle (Veh; tap water), WKY MPH (1.5 mg/kg/day), SHR Veh, SHR MPH. Individual administration was performed by gavage between P28-P55. Retinal physiology and structure were evaluated at P56 followed by tissue collection and analysis. The ADHD animal model presents the retinal structural, functional, and neuronal deficits, as well as the microglial reactivity, astrogliosis, blood-retinal barrier (BRB) hyperpermeability and a pro-inflammatory status. In this model, MPH had a beneficial effect on reducing microgliosis, BRB dysfunction, and inflammatory response, but did not correct the neuronal and functional alterations in the retina. Curiously, in the control animals, MPH showed an opposite effect since it impaired the retinal function, neuronal cells, and BRB integrity, and also promoted both microglia reactivity and upregulation of pro-inflammatory mediators. This study unveils the retinal alterations in ADHD and the opposite effects induced by MPH in the retina of ADHD and the control animal models.

Identifiants

pubmed: 37107312
pii: antiox12040937
doi: 10.3390/antiox12040937
pmc: PMC10135983
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fundação para a Ciência e Tecnologia
ID : PhD fellowship 2021,04797. BD, Strategic Projects UID/NEU/04539/2019 (CNC.IBILI), UIDB/04539/2020 and UIDP/04539/2020 (CIBB); COMPETE-FEDER (PO-CI-01-0145-FEDER-007440); Centro 2020 Regional Operational Program: BRAINHEALTH 2020 (CENTRO-01-0145-FEDER-0000
Organisme : Calouste Gulbenkian Foundation
ID : Grant 243101

Références

Neuropharmacology. 2013 Feb;65:74-82
pubmed: 22960442
Nat Rev Neurol. 2013 Jan;9(1):44-53
pubmed: 23165340
JAMA. 2009 Sep 9;302(10):1084-91
pubmed: 19738093
Sci Rep. 2020 Jun 15;10(1):9619
pubmed: 32541823
J Control Release. 2022 Mar;343:469-481
pubmed: 35131370
Brain Behav Immun. 2018 Feb;68:169-182
pubmed: 29061363
J Atten Disord. 2018 May;22(7):619-626
pubmed: 27535944
Brain. 2016 Nov 1;139(11):2827-2843
pubmed: 27412389
Biomed Res Int. 2014;2014:406960
pubmed: 25136585
J Cereb Blood Flow Metab. 2015 Aug;35(8):1260-71
pubmed: 25899299
Exp Clin Psychopharmacol. 2013 Oct;21(5):363-74
pubmed: 24099357
Neuropsychopharmacology. 2021 Dec;46(13):2358-2370
pubmed: 34400780
Neurosci Biobehav Rev. 2000 Jan;24(1):31-9
pubmed: 10654658
Neuropsychiatr Dis Treat. 2008 Oct;4(5):893-918
pubmed: 19183781
JAMA Ophthalmol. 2021 Feb 1;139(2):182-188
pubmed: 33355613
Biol Psychiatry. 2021 Feb 15;89(4):386-397
pubmed: 33069367
Sci Rep. 2022 May 9;12(1):7610
pubmed: 35534594
Psychiatry Res. 2018 Dec;270:786-791
pubmed: 30551326
Biomed Rep. 2021 May;14(5):47
pubmed: 33786176
Compr Psychiatry. 2016 May;67:66-72
pubmed: 27095337
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14259-64
pubmed: 25225387
J Affect Disord. 2018 Feb;227:665-671
pubmed: 29174740
Vision Res. 2009 Jan;49(1):115-26
pubmed: 18952118
Am J Med Genet B Neuropsychiatr Genet. 2019 Jun;180(4):272-286
pubmed: 30953404
Neurophysiol Clin. 2010 Jun;40(3):137-49
pubmed: 20513613
Neurosci Biobehav Rev. 2019 May;100:166-179
pubmed: 30826386
Int Ophthalmol. 2021 Sep;41(9):3211-3221
pubmed: 34014463
Int J Mol Sci. 2022 Apr 19;23(9):
pubmed: 35562891
Front Immunol. 2019 Aug 20;10:1975
pubmed: 31481963
Lancet Psychiatry. 2017 Apr;4(4):310-319
pubmed: 28219628
PLoS One. 2013 May 31;8(5):e64949
pubmed: 23741431
Int J Mol Sci. 2019 Sep 19;20(18):
pubmed: 31546829
Eur J Clin Invest. 2022 Apr;52(4):e13694
pubmed: 34694635
PLoS One. 2011;6(12):e29583
pubmed: 22216322
Neuroscience. 2015 Sep 10;303:364-77
pubmed: 26166731
Mol Neurobiol. 2018 Mar;55(3):2056-2069
pubmed: 28283882
Lancet. 2020 Feb 8;395(10222):450-462
pubmed: 31982036
Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):393-416
pubmed: 35697392
Dialogues Clin Neurosci. 2013 Sep;15(3):359-84
pubmed: 24174907
Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):19854-19865
pubmed: 32759214
Curr Eye Res. 2020 Nov;45(11):1422-1429
pubmed: 32255364
Glia. 2014 Dec;62(12):1943-54
pubmed: 24989686
Acta Ophthalmol. 2008 May;86(3):259-64
pubmed: 18494726
Optom Vis Sci. 2016 May;93(5):459-65
pubmed: 26855242
Int J Mol Sci. 2021 Dec 21;23(1):
pubmed: 35008441
Neuroscience. 2014 Aug 22;274:289-98
pubmed: 24905438
Neuropsychopharmacology. 2017 Sep;42(10):2096-2104
pubmed: 28176786
Int J Mol Sci. 2018 Oct 27;19(11):
pubmed: 30373222
Exp Eye Res. 2020 Apr;193:107964
pubmed: 32044305
Prog Retin Eye Res. 2016 Mar;51:1-40
pubmed: 26113209
J AAPOS. 2013 Oct;17(5):507-11
pubmed: 24160972
Mediators Inflamm. 2015;2015:673090
pubmed: 25873768
Glia. 2016 Sep;64(9):1479-91
pubmed: 27314452
J Neural Transm (Vienna). 2008;115(2):235-9
pubmed: 17896072
Transl Neurodegener. 2020 Nov 26;9(1):42
pubmed: 33239064
Schizophr Res. 2020 May;219:77-83
pubmed: 31053491
Neurosci Biobehav Rev. 2003 Nov;27(7):639-51
pubmed: 14624808
J Pharmacol Sci. 2019 May;140(1):86-93
pubmed: 31109761
Int J Toxicol. 2018 Nov/Dec;37(6):448-456
pubmed: 30373422
Invest Ophthalmol Vis Sci. 2022 May 2;63(5):5
pubmed: 35506936
Cell Mol Life Sci. 2016 Dec;73(24):4701-4716
pubmed: 27376435
Eur Neuropsychopharmacol. 2019 Dec;29(2):195-210
pubmed: 30554860
Neuropsychopharmacology. 2017 May;42(6):1326-1337
pubmed: 27910862
Braz J Psychiatry. 2020;42(3):309-313
pubmed: 32022160
Biol Psychiatry. 2005 Jun 1;57(11):1239-47
pubmed: 15949994
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9
pubmed: 23264323
Cell Mol Life Sci. 2019 Jul;76(14):2739-2760
pubmed: 31016348
Exp Eye Res. 2014 Oct;127:91-103
pubmed: 25064602
Int J Mol Sci. 2021 Feb 19;22(4):
pubmed: 33669765
Cell Death Dis. 2017 Oct 5;8(10):e3065
pubmed: 28981089
Int Ophthalmol. 2020 Nov;40(11):3105-3113
pubmed: 32666167
Neuromolecular Med. 2017 Mar;19(1):101-112
pubmed: 27553015
Mol Psychiatry. 2021 Sep;26(9):4958-4967
pubmed: 32439845

Auteurs

Eliane S Sanches (ES)

Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-531 Coimbra, Portugal.

Raquel Boia (R)

Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-531 Coimbra, Portugal.
Clinical Academic Center of Coimbra (CACC), 3004-561 Coimbra, Portugal.

Ricardo A Leitão (RA)

Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-531 Coimbra, Portugal.

Maria H Madeira (MH)

Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-531 Coimbra, Portugal.

Carlos A Fontes-Ribeiro (CA)

Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-531 Coimbra, Portugal.
Clinical Academic Center of Coimbra (CACC), 3004-561 Coimbra, Portugal.

António Francisco Ambrósio (AF)

Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-531 Coimbra, Portugal.
Clinical Academic Center of Coimbra (CACC), 3004-561 Coimbra, Portugal.
Association for Innovation and Biomedical Research on Light and Image (AIBILI), 3000-548 Coimbra, Portugal.

Rosa Fernandes (R)

Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-531 Coimbra, Portugal.
Clinical Academic Center of Coimbra (CACC), 3004-561 Coimbra, Portugal.
Association for Innovation and Biomedical Research on Light and Image (AIBILI), 3000-548 Coimbra, Portugal.

Ana Paula Silva (AP)

Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-531 Coimbra, Portugal.
Clinical Academic Center of Coimbra (CACC), 3004-561 Coimbra, Portugal.

Classifications MeSH